Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy. | Neoplasma;60(2): 129-34, 2013. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.

Fiala, O; Pesek, M; Finek, J; Krejci, J; Bortlicek, Z; Benesova, L; Minarik, M.

Affiliation

Fiala O; Department of Oncology and Radiotherapy, Charles University Prague, Czech Republic. fiala.o@centrum.cz

Neoplasma ; 60(2): 129-34, 2013.

Article in En | MEDLINE | ID: mdl-23259780

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / Lung Neoplasms / Antineoplastic Agents Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Neoplasma Year: 2013 Document type: Article Affiliation country: Country of publication:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / Lung Neoplasms / Antineoplastic Agents Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Neoplasma Year: 2013 Document type: Article Affiliation country: Country of publication: